Marked increase of neuronal prion protein immunoreactivity in Alzheimer's disease and human prion diseases

被引:0
|
作者
Voigtländer, T
Klöppel, S
Birner, P
Jarius, C
Flicker, H
Verghese-Nikolakaki, S
Sklaviadis, T
Guentchev, M
Budka, H
机构
[1] Univ Vienna, Inst Neurol, A-1097 Vienna, Austria
[2] Austrian Reference Ctr Human Prion Dis, A-1097 Vienna, Austria
[3] Univ Vienna, Dept Clin Pathol, A-1010 Vienna, Austria
[4] Aristotelian Univ Salonika, Inst Pharmaceut Sci, Thessaloniki, Greece
关键词
neurodegeneration; prion protein; oxidative stress; transmissible spongiform encephalopathy Alzheimer's disease;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In neurodegenerative disorders including Alzheimer's disease (AD), free radical damage to lipids, carbohydrates, proteins and DNA has been demonstrated to play a key pathogenetic role. In vitro studies have suggested a function of the cellular prion protein (PrPc) in the defense against oxidative stress. Therefore, we investigated the distribution of PrPc immunoreactivity in hippocampus (sectors CA4-CA1), subiculum (Sub), entorhinal (EC), and temporal cortex (TC) in sections from AD, human transmissible spongiform encephalopathy (TSE) and control brains. Compared to control cases, AD brains revealed an increase in the proportion of PrPc-immunoreactive neurons, which was statistically significant in CA2, Sub, and TC. In TSEs, a statistically significant increase of PrPc-immunoreactive neurons was observed in CA2, CAI, Sub, EC, and TC. In conclusion, our data show a striking up-regulation of PrPc in neurodegeneration and provide additional support for the concept that PrPc may be involved in the defense against oxidative stress.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 50 条
  • [21] Polymorphisms within the prion-like protein gene (Prnd) and their implications in human prion diseases, Alzheimer's disease and other neurological disorders
    Björn Schröder
    Bettina Franz
    Petra Hempfling
    Martin Selbert
    Thomas Jürgens
    Hans A. Kretzschmar
    Monika Bodemer
    Sigrid Poser
    Inga Zerr
    Human Genetics, 2001, 109 : 319 - 325
  • [22] Therapeutics in Alzheimer's and prion diseases
    Wisniewski, T
    Brown, DR
    Sigurdsson, EM
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 : 574 - 578
  • [23] Alzheimer's disease, cellular prion protein, and dolphins
    Di Guardo, Giovanni
    ALZHEIMERS & DEMENTIA, 2018, 14 (02) : 259 - 260
  • [24] IS ALZHEIMER'S DISEASE A PRION DISEASE?
    Segarra, C.
    Coste, J.
    VOX SANGUINIS, 2013, 105 : 192 - 192
  • [25] Prion protein aggregation assays in the diagnosis of human prion diseases
    Green, Alison J. E.
    FUTURE NEUROLOGY, 2015, 10 (03) : 217 - 228
  • [26] THE CONTROL OF PROTEIN SYNTHESIS IN PRION AND ALZHEIMER DISEASES
    Hajj, G. N.
    Roffe, M.
    Beraldo, F. H.
    Wasilewska-Sampaio, A. P.
    Hirata, P. H.
    Vorberg, I
    Castilho, B. A.
    Prado, M. A.
    Ferreira, S.
    Martins, V. R.
    JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 106 - 107
  • [27] The neurodegeneration in Alzheimer disease and the prion protein
    Forloni, Gianluigi
    Sclip, Alessandra
    Borsello, Tiziana
    Balducci, Claudia
    PRION, 2013, 7 (01) : 60 - 65
  • [28] Neuronal apoptosis in human prion diseases.
    Gray, F
    Dorandeu, A
    Wingertsmann, L
    Delisle, MB
    Budka, H
    Gambetti, P
    Ironside, JW
    Vital, C
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (05): : 493 - 493
  • [29] The prion principle and Alzheimer's disease Similarities to molecular mechanisms underlying prion diseases may help to refine Alzheimer's disease therapies
    Walker, Lary C.
    Jucker, Mathias
    SCIENCE, 2024, 385 (6715) : 1278 - 1279
  • [30] Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer's disease
    Shafiq, Mohsin
    Zafar, Saima
    Younas, Neelam
    Noor, Aneeqa
    Puig, Berta
    Altmeppen, Hermann Clemens
    Schmitz, Matthias
    Matschke, Jakob
    Ferrer, Isidre
    Glatzel, Markus
    Zerr, Inga
    MOLECULAR NEURODEGENERATION, 2021, 16 (01)